Angiology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst[PDF])
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by de Albuquerque, R. M.
Right arrow Articles by Bouskela, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Albuquerque, R. M.
Right arrow Articles by Bouskela, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on April 2, 2008
Angiology 2008, doi:10.1177/0003319707309656
© 2008 SAGE Publications

Article

Effects of Cilostazol and Pentoxifylline on Forearm Reactive Hyperemia Response, Lipid Profile, Oxidative Stress, and Inflammatory Markers in Patients With Intermittent Claudication

Renato Maranhao de Albuquerque, MD, MSc, Carlos Eduardo Virgini-Magalhaes, MD, Fernando Lncastre Sicuro, BS,, MSc, Daniel Alexandre Bottino, MD, PhD, and Eliete Bouskela, MD, PhD*

State University of Rio de Janeiro

* To whom correspondence should be addressed. E-mail: eliete_bouskela{at}yahoo.com.br.


   Abstract
Peripheral arterial disease may lead to lower limb claudication and increased risk of systemic vascular dysfunction. In this article, the authors have investigated the peripheral vascular dysfunction evaluating forearm blood flow using venous occlusion plethysmography, lipid profile, and C-reactive protein in 60 patients with moderate intermittent claudication treated during 20 weeks with placebo (n = 16), cilostazol (200 mg/d; n = 17), or pentoxifylline (1200 mg/d; n = 15) in a randomized double-blinded clinical trial, taking into account smoking. Forearm blood flow after reactive hyperemia response (FBFh) or oral nitroglycerine spray to evaluate endothelial-dependent and endothelial-independent vasodilation, respectively, pain-free and maximal walking distance, levels of C-reactive protein, triglycerides, cholesterol, low-density lipoprotein, and high-density lipoprotein–cholesterol in plasma were determined. The results showed that there was an improvement in the high-density lipoprotein–cholesterol, pain-free and maximal walking distance, and FBFh independent of treatment in nonsmoking patients. Cilostazol increased high-density lipoprotein–cholesterol level, maximal walking distance, and FBFh, whereas pentoxifylline reduced C-reactive protein level and increased maximal walking distance in total and nonsmoking groups. No treatment was effective in smokers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?